BLISS GVS PHARMA LTD.



November 21, 2022

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith a disclosure of Related Party Transactions in the specified format for the half year ended September 30, 2022.

Kindly take the same on your record.

Thanking you,

Yours faithfully, For **Bliss GVS Pharma Limited**

Aditi Bhatt Company Secretary

Encl: as above

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.								
S. No.	Details of the party (listed entity /subsidi ary) entering into the transact ion	Details of the counterparty		party transaction (see Note 5) transaction as approved by the audit committee (see Note 6a) (transactio to either party as a in during result of the transaction in the (see Note 1) reporting period in the transaction in the see Note 1)		In case any financial indebtedness is incurred to make or give loans, intercorporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments							
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nat ure of inde bte dne ss (loa n/ issu anc e of deb t/ any oth er etc.	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter- corporat e deposit/ investme nt	Inte rest Rat e (%)	Tenure	Secured / Unsecur ed	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)		
	Bliss GVS	Mr. S. N. Kamath	Promoter and Relative of	Payment of Rent	-	33.68	-	-	-	-	-	-	-	-	-	-		
	Pharma Limited	Ndilidili	Director (from 12.05.21)															

Bliss GVS Pharma Limited	Mr. S. N. Kamath	Promoter and Relative of Director (from 12.05.21)	Refundable deposit for Leave License	-	0	78.75	48.75	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Geeta N. Kamath	Relative of Director (from 12.05.21)	Payment of Rent	1	2.03	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Mrs. Shruti Vishal Rao	Director	Remuneration	-	33.00	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Dr. Vibha Gagan Sharma	Director	Remuneration	-	34.08	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Mr. Gagan Harsh Sharma	Managing Director	Remuneration	-	86.69	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Mr. Vishal Rao	Relative of Director	Remuneration	-	32.70	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Mr. Vipul B. Thakkar	Key management personnel of entity or parent (resigned w.e.f. 30.06.2022)	Remuneration	-	43.04	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Ms. Aditi Bhatt	Key management personnel of entity or parent	Remuneration	1	8.90	-	1	-	1	-	-	-	-	-	-
Bliss GVS Pharma Limited	Bliss GVS Internatio nal Pte Ltd	Wholly Owned Subsidiary	Investment in Share Capital		-	22.58	22.58	-	-	-	Investme nt in equity	NA	NA	Unsecur ed	Investme nt made for business purpose
Bliss GVS Pharma Limited	Bliss GVS Internatio nal Pte Ltd	Wholly Owned Subsidiary	Interest Income/ Receivable	450	196.51	507.42	712.91	-	-	-	-	-	-	-	-

Bliss GVS Pharma Limited	Bliss GVS Internatio nal Pte Ltd	Wholly Owned Subsidiary	Loan and Advances	15000	121.48	8070.93	8804.92	-	-	-	Loan	4.5 %	Repayab le on Demand	Unsecur ed	Loan utilised for business
Bliss GVS Pharma Limited	Bliss GVS Internatio nal Pte Ltd	Wholly Owned Subsidiary	Sale of Goods	500	-	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Bliss GVS Internatio nal Pte Ltd	Wholly Owned Subsidiary	Purchase of Goods	20	-	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Labour Charges and purchases of goods	100	7.45	-	-	-	1	-	-	-	-	-	-
Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Dividend Received	13	12.60		-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Investment in Share Capital	2500		1,803.00	1,803.00	1	1	-	Investme nt in equity	NA	NA	Unsecur ed	Investme nt made for business purpose
Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Interest Income/ Receivable	1	_	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Sale of Goods	250	0.63	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Loans and Advances	100	-	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Asterisk Lifescienc es Limited (UK)	Wholly Owned Subsidiary	Investment In Share Capital	-	-	0.10	0.10	-	-	-	Investme nt in equity	NA	NA	Unsecur ed	Investme nt made for business purpose

Bliss	Asterisk	Wholly Owned	Loans and	1000	-	19.80	18.05	_	_	-	-	-	-	_	-
GVS Pharma Limited	Lifescienc es Limited (UK)	Subsidiary	Advances												
Bliss GVS Pharma Limited	Asterisk Lifescienc es Limited (UK)	Wholly Owned Subsidiary	Interest Income /Receivable	1	0.41	2.50	2.68	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Asterisk Lifescienc es GH Limited	Step-down Subsidiary	Investment in Share Capital	10	-	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Asterisk Lifescienc es GH Limited	Step-down Subsidiary	Reimbursement of Expenses received	50	0.82	-	-	-	-	-	-	-	1	-	-
Bliss GVS Pharma Limited	Asterisk Lifescienc es GH Limited	Step-down Subsidiary	Sale of Goods	15000	2932.94	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Asterisk Lifescienc es GH Limited	Step-down Subsidiary	Loans and Advances	1000	-	-	-	-	-	-	-	-	1	-	-
Bliss GVS Pharma Limited	Greenlife Bliss Healthcar e	Step-down Subsidiary	Loans and Advances	100	-	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	Greenlife Bliss Healthcar e	Step-down Subsidiary	Sale of Goods	100	•	-	-	-	-	-	-	-	ı	-	-
Bliss GVS Pharma Limited	Greenlife Bliss Healthcar e	Step-down Subsidiary	Purchase of Goods	10	-	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma Limited	EIPII Exports Pvt Ltd.	Step-down Subsidiary	Sale of Goods	500	52.32	-	-	-	-	-	-	-	-	-	-
Bliss GVS Pharma	Lozen Pharma Pvt Ltd.	Directors are Members/Share holders	Purchase of Goods	750	195.49	-	-								

	Limited															
	Bliss GVS Pharma Limited	Asterisk Lifescienc es DRC	Step-down Subsidiary	Sale of goods	15000	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifescienc es DRC	Step-down Subsidiary	Loans and Advances	1000	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifescienc es DRC	Step-down Subsidiary	Reimbursement of Expenses	50	2.13	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifescienc es DRC	Step-down Subsidiary	Investment In Share Capital	10	-	-	-	-	-	1	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuitie s (I) Pvt Ltd	Directors are Members/Share holders	Purchase of Goods	25	-	-	-	-	-	1	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuitie s (I) Pvt Ltd	Directors are Members/Share holders	Reimbursement of Expenses	3	-	-	-	-	1	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuitie s (I) Pvt Ltd	Directors are Members/Share holders	Sales of Goods	5	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Bliss GVS Charitable Trust	Enterprise over which KMP exercises significant influence	Donation	50	25.00	-	-	-	-	-	-	-	-	-	-
Total (of Note 6b)																

Note: Foreign balances are reinstated wherever applicable

Notes:

- 1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- 2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- 3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- 4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
- 5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- 6. In case of a multi-year related party transaction:
- a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
- b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
- 7. "Cost" refers to the cost of borrowed funds for the listed entity.
- 8. PAN will not be displayed on the website of the Stock Exchange(s).
- 9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.